Immunohistochemical profiles of I<scp>DH</scp>1, <scp>MGMT</scp> and <scp>P</scp>53: Practical significance for prognostication of patients with diffuse gliomas

Ogura, Ryosuke; Tsukamoto, Yoshihiro; Natsumeda, Manabu; Isogawa, Mizuho; Aoki, Hiroshi; Kobayashi, Tsutomu; Yoshida, Seiichi; Okamoto, Kosuke; Takahashi, Hitoshi; Fujii, Yukihiko; Kakita, Akiyoshi

doi:10.1111/neup.12196

Cited by 58 publications

(43 citation statements)

References 55 publications

(105 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies suggested that, hypermethylation of the O‐6 methylguanine DNA‐methyltransferase (MGMT) promoter is a predictor of therapeutic response and good prognosis in patients with GBM . Our study has certain drawbacks.…”

Section: Discussionmentioning

confidence: 99%

Carbonic anhydrase IX is a prognostic biomarker in glioblastoma multiforme

et al. 2018

View full text Add to dashboard Cite

The identification of prognostic factors in patients with glioblastoma multiforme (GBM) represents an area of increasing interest. Carbonic anhydrase IX (CA-IX), a hypoxia marker, correlates with tumor progression in a variety of human cancers. However, the role of CA-IX in GBM remains largely unknown. In the present study, we evaluated the prognostic role of CA-IX in GBM patients. In total, 66 consecutive patients with GBM who received concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide were retrospectively reviewed, and all patients received temozolomide chemotherapy for at least 3 months. Kaplan-Meier curves and log-rank tests were used for analysis of progression-free survival (PFS) and overall survival (OS), and a multivariate Cox proportional hazard model was employed to identify factors with an independent effect on survival. The median OS was longer in patients with low levels of CA-IX expression (18 months) compared to patients overexpressing CA-IX (9 months) (P = 0.004). There was not a statistically significant difference in median PFS (3.5 vs. 8 months, P = 0.054) between patients with high or low levels of CA-IX expression. In multivariate analysis, the variables that were identified as significant prognostic factors for OS were preoperative Karnofsky performance scale score (KPS) (hazard ratio (HR), 3.703; P = 0.001), CA-IX overexpression (HR, 1.967; P = 0.019), and incomplete adjuvant temozolomide treatment (HR, 2.241; P = 0.003) and gross-total resection (HR, 1.956; P = 0.034). Our findings indicated that CA-IX may be a potential prognostic biomarker in the treatment of GBM.

show abstract

Section: Discussionmentioning

confidence: 99%

Carbonic anhydrase IX is a prognostic biomarker in glioblastoma multiforme

et al. 2018

View full text Add to dashboard Cite

show abstract

“…19 Of the GBM tumors, 15.2% (24/158) were positive for PD-1+ TIL and TP53 mutation, and 1.8% (4/227) were positive for PD-L1 and TP53 mutation (Fig. 4C), indicating that this mutation does not frequently coassociate with immune checkpoint expression (P ¼ .79 for correlation with PD-1+ TIL and P ¼ 1 for PD-L1, respectively).…”

Section: Garber Et Al: Pd-1/pd-l1 Expressionmentioning

confidence: 98%

Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies

Garber

Hashimoto

Weathers

et al. 2016

NEUONC

118

100

View full text Add to dashboard Cite

“…In gliomas, immunodetection of p53 upregulation is indicative of the presence of p53 abnormalities and poor prognosis. [33][34][35] So far, the association between p53 in diffuse astrocytoma and oligodendroglioma and seizure control has not been investigated. In preclinical studies on rats, normal p53 levels had an inhibitory effect on epilepsy.…”

Section: The Role Of P53 In the Control Of Seizures In Patients With Lggmentioning

confidence: 99%

Molecular Aberrations Associated with Seizure Control in Diffuse Astrocytic and Oligodendroglial Tumors

Suzuki

Mikuni

Sugita

et al. 2020

Neurol. Med. Chir.(Tokyo)

View full text Add to dashboard Cite

Diffuse astrocytic and oligodendroglial tumors are frequently associated with symptomatic epilepsy, and predictive seizure control is important for the improvement of patient quality of life. To elucidate the factors related to drug resistance of brain tumor-associated epilepsy from a pathological perspective. From January 2012 to October 2017, 36 patients diagnosed with diffuse astrocytic or oligodendroglial tumors were included. Assessment for seizure control was performed according to the Engel classification of seizures. Patient clinical, radiological, and pathological data were stratified based on the following 16 variables: age, sex, location of tumor, existence of the preoperative seizure, extent of resection, administration of temozolomide, radiation therapy, recurrence, Karnofsky performance scale, isocitrate dehydrogenase 1, 1p/19q co-deletion, Olig2, platelet-derived growth factor receptor alpha, p53, ATRX, and Ki67. These factors were compared between the well-controlled group and drug-resistant seizure group. Twenty-seven patients experienced seizures; of these, 14 cases were well-controlled, and 13 cases were drug-resistant. Neither clinical nor radiological characteristics were significantly different between these two groups, though p53 immunodetection levels were significantly higher, and the frequency of 1p/19q co-deletion was significantly lower in the group with drug-resistant seizures than in the wellcontrolled group. In the multivariate analysis, only one item was selected according to stepwise methods, and a significant difference was observed for p53 (OR, 21.600; 95% CI, 2.135-218.579; P = 0.009). Upregulation of p53 may be a molecular mechanism underlying drug resistant epilepsy associated with diffuse astrocytic and oligodendroglial tumors.

show abstract

Immunohistochemical profiles of IDH1, MGMT and P53: Practical significance for prognostication of patients with diffuse gliomas

Cited by 58 publications

References 55 publications

Carbonic anhydrase IX is a prognostic biomarker in glioblastoma multiforme

Carbonic anhydrase IX is a prognostic biomarker in glioblastoma multiforme

Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies

Molecular Aberrations Associated with Seizure Control in Diffuse Astrocytic and Oligodendroglial Tumors

Contact Info

Product

Resources

About